The frequent UCP2 -866G>A polymorphism protects against insulin resistance and is associated with obesity

A study of obesity and related metabolic traits among 17,636 Danes

Dalgaard, Louise Torp; Andersen, Gitte; Justesen, Johanne Marie; Anthonsen, Stine; Nielsen, Trine; Thørner, Lise Wegner; Witte, Daniel; Jørgensen, Torben; Clausen, Jesper; Lauritzen, Torsten; Holmkvist, Johan; Hansen, Torben; Pedersen, Oluf

Published in:
International Journal of Obesity

DOI:
10.1038/ijo.2012.22

Publication date:
2013

Document Version
Early version, also known as pre-print

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.

Take down policy
If you believe that this document breaches copyright please contact rucforsk@ruc.dk providing details, and we will remove access to the work immediately and investigate your claim.
ORIGINAL ARTICLE
The frequent UCP2 −866G>A polymorphism protects against insulin resistance and is associated with obesity: a study of obesity and related metabolic traits among 17 636 Danes

G Andersen1,10, LT Dalgaard2,10, JM Justesen3, S Anthonsen1,2, T Nielsen3, LW Thørner1, D Witte4, T Jørgensen5,6, JO Clausen4, T Lauritzen7, J Holmkvist1, T Hansen1,3,8 and O Pedersen1,3,6,9

CONTEXT: Uncoupling protein 2 (UCP2) is involved in regulating ATP synthesis, generation of reactive oxygen species and glucose-stimulated insulin secretion in β-cells. Polymorphisms in UCP2 may be associated with obesity and type 2 diabetes mellitus.

OBJECTIVE: To determine the influence of a functional UCP2 promoter polymorphism (−866G>A, rs659366) on obesity, type 2 diabetes and intermediary metabolic traits. Furthermore, to include these and previously published data in a meta-analysis of this variant with respect to its impact on obesity and type 2 diabetes.

DESIGN: We genotyped UCP2 rs659366 in a total of 17 636 Danish individuals and established case-control studies of obese and non-obese subjects and of type 2 diabetic and glucose-tolerant subjects. Meta-analyses were made in own data set and in publicly available data sets. Quantitative traits relevant for obesity and type 2 diabetes were analysed within separate study populations.

RESULTS: We found no consistent associations between the UCP2 −866G-allele and obesity or type 2 diabetes. Yet, a meta-analysis of data from 12 984 subjects showed an association with obesity (GA vs GG odds ratio (OR) (95% confidence interval (CI)): 0.894(0.826-0.968)P=0.00562, and AA vs GG OR(95% CI): 0.892(0.800-0.996),P=0.0415). Moreover, a meta-analysis for type 2 diabetes of 15 107 individuals showed no association. The −866G-allele was associated with elevated fasting serum insulin levels (P=0.002) and HOMA insulin resistance index (P=0.0007). Insulin sensitivity measured during intravenous glucose tolerance test in young Caucasian subjects (n=377) was decreased in carriers of the GG genotype (P=0.05).

CONCLUSIONS: The UCP2 −866G-allele is associated with decreased insulin sensitivity in Danish subjects and is associated with obesity in a combined meta-analysis.

Keywords: diabetes; insulin sensitivity; genetics; uncoupling protein 2; −866G/A polymorphism; rs659366

INTRODUCTION
Uncoupling protein 2 (UCP2) is a mitochondrial transporter that un couples oxidative phosphorylation via induced proton leak from the inner mitochondrial membrane (reviewed in Dalgaard and Pedersen1 and Dalgaard2). It is ubiquitously expressed3,4 and overexpression of UCP2 is reported to inhibit glucose-stimulated insulin secretion in pancreatic rat islets5 and INS-1 β-cells.6 Ucp2−/− mice have higher pancreatic islet ATP levels, increased glucose-stimulated insulin secretion and are protected against glucose toxicity in β-cells in some,7,8 but not all reports,9 whereas on a high-fat diet they showed increased insulin secretion and decreased plasma triglyceride concentrations compared with wild-type mice.10 However, no effect of Ucp2 gene disruption on obesity was observed, even upon a high-fat diet;11 whereas, short-term inhibition of Ucp2 using antisense oligonucleotides ameliorated both insulin resistance as well as improved insulin secretion in a diet-induced mouse model.12 In comparison, missense mutations of UCP2 were identified in two families in which congenital hyperinsulinaemia occurred in young children.13 Each of the two families carried their own mutations, which segregated with the disease and which changed amino acids conserved between species, and functional studies supported a lack of function of mutated UCP2 proteins. Unfortunately, no phenotype information was given on adult members of these two families. Thus, there is clear evidence that UCP2 ablation modulates insulin secretion in mice, and suggestive evidence in humans. This raises the relevant question whether there is an effect of common genetic variation in the Ucp2 gene in human subjects.
A frequent \(--866G \to A\) polymorphism (rs659366) has been identified in UC2P.\(^4\) It was found to be located in the core promoter\(^5\) in a region with putative binding sites for two \(\beta\)-cell transcription factors. The \(--866A\)-allele has been reported to associate with both decreased and increased adipose tissue Ucp2 mRNA levels;\(^4,16\) however, reporter constructs with the \(--866A\)-allele show increased activity in adipocytes\(^4\) and in \(\beta\)-cells.\(^17\) It is therefore most likely that the \(--866A\)-allele causes increased promoter activity and increases Ucp2 mRNA levels.

The \(G\)-variant was shown to associate with an increased risk of obesity among 596 and 791 white Europeans.\(^14\) No consensus has been achieved regarding the association between \(--866G \to A\) and adiposity; contrasting the original observation,\(^14\) a range of smaller or equally sized studies reported no association with levels of body mass index (BMI) or waist-to-hip ratio.\(^5,18-27\) However, among 2695 healthy, British men, the AA genotype was more prevalent among obese participants,\(^28\) and a haplotype containing the \(--866G\)-allele showed association with childhood obesity.\(^29\) Also, a modestly increased 'fat BMI' was reported in Danish obese men carrying the A-allele.\(^30\) No association with juvenile-onset obesity was observed.\(^23,27\) Therefore, it is still not clear whether this variant is associated with obesity; in order to determine this, larger studies and collective meta-analyses are needed.

A number of studies have examined the relationship of \(--866G \to A\) with components of the metabolic syndrome, such as hyperglycaemia, obesity, hypertension and dyslipidaemia (reviewed in Chan and Harper\(^32\) and Fisler and Warden\(^33\)). Assuming that a more subtle intermediary obesity-related phenotype is affected by the \(--866G \to A\) polymorphism, a number of interesting observations have been made; among 681 French type 2 diabetic patients the UC2P G-allele was associated with elevated triglyceride and total cholesterol concentrations and increased risk of dyslipidaemia\(^34\) and decreased HDL (high-density lipoprotein)-cholesterol levels were reported among 658 Korean women carrying the A-allele.\(^25\) Contrary, a lack of association with lipid levels has also been reported.\(^18,20,23\)

For type 2 diabetes the general notion is also unclear, as reports have been made of association of the \(--866G \to A\) with increased\(^20,35,36\) and decreased\(^16,23,37,38\) risk of type 2 diabetes as well as no association at all.\(^24,34,39\) An early onset of type 2 diabetes has been related to both the A-allele\(^17,36\) and the G-allele\(^37\) and an early requirement for insulin treatment has been observed among A-allele carriers.\(^17,34\) Lower basal insulin secretion was initially reported among A-allele carriers,\(^14\) but was contrasted by subsequent studies\(^5,15,21,23\) where no association was found. The A-allele was related to reduced glucose-stimulated first-phase insulin secretion among 137 Japanese type 2 diabetic patients\(^17\) and in isolated pancreatic islets from non-diabetic subjects,\(^19\) which is in accordance with the A-allele causing increased promoter activity and presumably also increased UC2P protein levels. Also, observations of a lower disposition index have been made,\(^19,35\) although this could be induced by changes in insulin sensitivity rather than insulin secretory capacity. Indeed, increased insulin resistance assessed by a hyperinsulinaemic-euglycaemic clamp or an IVGTT (intravenous glucose tolerance test) among A-allele carriers has been reported in some\(^6,35,36\) but not all\(^19,21,29\) studies. A recent meta-analysis of the \(--866G/A\) polymorphism for association with type 2 diabetes mellitus concluded that this variant does not confer increased risk of diabetes.\(^40\)

Thus, this variant has been extensively characterized in a number of small-scale studies with variable outcomes and it is therefore highly relevant to perform studies in larger, yet still well-characterized, study groups in order to establish the role of the \(UC2P \to --866G \to A\) polymorphism. Many of these early studies were underpowered compared with their identified effect sizes and some are likely to be false-positive reports. Therefore, using data from a total of 17,636 Danes, we aim in the present study to clarify the relationship of the \(UC2P \to --866G \to A\) polymorphism with a range of metabolic traits, type 2 diabetes and obesity.

In addition, we carried out meta-analyses of obesity and type 2 diabetes by combining our data with previously published and publicly available data. Our conclusions from this study are that the G-allele of the \(--866G\) polymorphism is associated with obesity in one of our study groups and in a combined meta-analysis, whereas this variant is not associated with type 2 diabetes either in our study groups or in the combined meta-analysis. Furthermore, the G-allele of this variant is consistently associated with increased insulin resistance.

**MATERIALS AND METHODS**

**Participants**

The UC2P rs659366 polymorphism was genotyped in 17,636 Danes comprising (1) the population-based Inter99 sample of middle-aged Danes sampled at Research Centre for Prevention and Health (\(n = 6126\), clinical trial reg. no. NCT00289237),\(^41\) (2) type 2 diabetic patients sampled through the out-patient clinic at Steno Diabetes Center (\(n = 1720\), (3) a population-based group of middle-aged glucose-tolerant subjects recruited from Steno Diabetes Center (\(n = 733\), (4) the ADDITION study group sampled through the Department of General Practice at University of Aarhus (\(n = 6644\), clinical trial reg. no. NCT00237548), which is a population-based, high-risk screening and intervention study for type 2 diabetes in general practice\(^38\) and (5) a population-based sample of young, healthy Danish Caucasians recruited from Research Centre for Prevention and Health (\(n = 377\)). Clinical characteristics have been described.\(^34,44\) A part of study sample 3 (32\%) was also investigated in relation to rs659366 in a previous publication.\(^15\)

Study groups 1 and 3 underwent a standard 75-g oral glucose tolerance test and study group 5 was examined using a frequently sampled tolbutamide-modified IVGTT.\(^45\) Informed consent was obtained from all subjects before participation. The study was approved by the Ethical Committee of Copenhagen County and was in accordance with the principles of the Helsinki Declaration. Type 2 diabetes and intermediary stages were defined according to the WHO criteria.\(^46\)

For case-control studies of obesity, cases were defined as having a BMI \(\geq 30\) kg m\(^{-2}\) and control subjects as having a BMI < 25 kg m\(^{-2}\). Dyslipidaemia was defined as fasting serum triglycerides \(\geq 1.7\) mmol l\(^{-1}\) or HDL-cholesterol < 0.9 mmol l\(^{-1}\) for men or < 1.0 mmol l\(^{-1}\) for women and/or current or previous treatment with lipid-lowering drugs. Hypertension was defined as mean systolic blood pressure \(\geq 140\) mm Hg and/or mean diastolic blood pressure \(\geq 90\) mm Hg, and/or current or previous treatment with antihypertensive drugs.

Biochemical and anthropometrical measurements

Height and body weight were measured in light indoor clothes and without shoes, and BMI was calculated as weight (kg)/height (m)\(^2\). Waist circumference was measured in the standing position midway between the iliac crest and the lower costal margin and hip circumference at its maximum. Blood samples were drawn after a 12-hour overnight fast. Plasma glucose was analysed by a glucose oxidase method (GranuTest, Merck, Darmstadt, Germany). HbA\(_1\)C was measured by ion-exchange high-performance liquid chromatography (normal reference range: 4.1-6.4\%). Serum insulin (excluding des\(^5\) and intact proinsulin) was measured using the AutoDELFIA insulin kit (Perkin-Elmer Wallac, Turku, Finland). Serum triglyceride and total- and HDL-cholesterol were analysed using enzymatic colorimetric methods (GPO-PAP and CHOD-PAP, Roche Molecular Biochemicals, Mannheim, Germany). HOMA-IR was calculated as fasting plasma glucose (mmol l\(^{-1}\)) multiplied by fasting serum insulin (pmol l\(^{-1}\)) and divided by 22.5. BIGGT-Si was calculated as described.\(^47\)

**Genotyping**

The UC2P rs659366 polymorphism was genotyped using KASPar (KBioscience, Hoddesdon, UK). Discordance between 965 random duplicate samples included in the genotyping was 0\% and the genotyping
success rate was 97%. All genotype groups obeyed Hardy–Weinberg equilibrium.

Statistical analyses
Fishé’s exact test was applied to examine differences in allele frequencies, and logistic regression with adjustment for age and sex was applied to examine differences in genotype distributions between affected and unaffected subjects. A general linear model was used to test quantitative variables for differences between genotype groups among non-diabetic and untreated subjects. Quantitative traits were analysed with age, sex and BMI as covariates, and BMI was corrected for age and sex. An additive genetic model was used to compare the effects of carrying 0, 1 or 2 G-alleles. Meta-analyses were performed as described48 and only studies providing complete information on numbers of subjects of each genotype were eligible for inclusion. Population and comparisons for these by genotype are therefore not completely investigated traits are correlated (obesity, type 2 diabetes, insulin resistance) for type 2 diabetes, there were no differences in minor allele obesity. However, the results from the ADDITION study (Table 1). The genotype distributions showed no evidence for association with obesity (Table 1).

RESULTS

Obesity case–control studies

The UCP2 –866G>A polymorphism was genotyped in 17 636 Danes, and we carried out case–control studies of obesity (BMI <25 kg m⁻² vs BMI ≥30 kg m⁻²) and WHO-defined type 2 diabetes. The case–control study of obesity was performed separately for the Steno/Inter99 and ADDITION study samples due to differences in ascertainment protocols, and in the Steno/Inter99 sample (n = 4700) we observed a nominal association with –866G>A (Table 1). The genotype distributions showed that the GG and GA genotypes were more prevalent in obese subjects of the Steno/Inter99 groups, indicating that the G-allele predisposes to obesity. However, the results from the ADDITION study (n = 4022) showed no evidence for association with obesity (Table 1).

Type 2 diabetes mellitus case–control study

For type 2 diabetes, there were no differences in minor allele frequencies or genotype distributions between cases (n = 3338)

Table 1. Genotype distribution and minor allele frequencies of the UCP2 –866G>A polymorphism for the participants stratified according to obesity

<table>
<thead>
<tr>
<th>BMI &lt;25 kg m⁻²</th>
<th>BMI ≥30 kg m⁻²</th>
<th>( P_{GD} )</th>
<th>( P_{MAF} )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steno/Inter99</td>
<td>n = 3153</td>
<td>n = 1547</td>
<td></td>
</tr>
<tr>
<td>GG</td>
<td>1133 (36)</td>
<td>583 (38)</td>
<td>0.03</td>
</tr>
<tr>
<td>GA</td>
<td>1499 (48)</td>
<td>754 (49)</td>
<td>0.03</td>
</tr>
<tr>
<td>AA</td>
<td>521 (17)</td>
<td>210 (14)</td>
<td>0.03</td>
</tr>
<tr>
<td>MAF (95% CI)</td>
<td>40.3 (39.1-41.5)</td>
<td>37.9 (36.2-39.7)</td>
<td>0.03</td>
</tr>
<tr>
<td>ADDITION</td>
<td>n = 1567</td>
<td>n = 2455</td>
<td></td>
</tr>
<tr>
<td>GG</td>
<td>534 (34)</td>
<td>874 (36)</td>
<td>0.2</td>
</tr>
<tr>
<td>GA</td>
<td>793 (51)</td>
<td>1183 (48)</td>
<td>0.02</td>
</tr>
<tr>
<td>AA</td>
<td>234 (15)</td>
<td>398 (16)</td>
<td>0.02</td>
</tr>
<tr>
<td>MAF (95% CI)</td>
<td>40.4 (38.7-42.2)</td>
<td>40.3 (38.9-41.7)</td>
<td>0.9</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; CI, confidence interval; GD, genotype distribution; MAF, minor allele frequency. Data are number of subjects with each genotype (% of each group) and MAF in percentages. All \( P \)-values were calculated using Fisher’s exact test and comparing genotype distributions (\( P_{GD} \)) and MAFs (\( P_{MAF} \)). Also, logistic regression was applied with adjustment for age and sex; however, this did not change the results. All genotype groups obeyed Hardy–Weinberg equilibrium.

and controls (n = 4904) (Supplementary Table A). Moreover, when analysing the ADDITION cohort prospectively, genotype distributions and minor allele frequencies were similar among non-diabetic people who converted to type 2 diabetes after a 5-year follow-up (GG 67, GA 82, AA 18) and those who did not convert (GG 1330, GA 1660, AA 586). There was no difference in the age of onset of diabetes in the different genotype groups and additional exploratory association studies of dyslipidaemia and hypertension were all negative (data not shown).

Meta-analysis for impact of UCP2 –866G>A on obesity and type 2 diabetes

We carried out a meta-analysis of the UCP2 –866G>A polymorphism in relation to obesity and type 2 diabetes using the data obtained from the present study along with available data from previously published reports (Figure 1). For type 2 diabetes, the included studies were highly heterogeneous (\( P = 1.4 \times 10^{-5} \))—probably due to large ethnic differences20,21,23,25,38—and no overall association was observed (\( P = 0.3 \)). Among studies of obesity, homogeneity was nearly obtained (\( P = 0.02 \)) when excluding studies of Asian subjects50,51 which amounted to 4% of subjects. There was an overall association of the –866G>A polymorphism with obesity (\( P = 0.003 \)) (Figure 1). The odds ratio in the meta-analysis was 0.89 for the GA or AA genotypes vs the GG risk genotype in a total of 12 984 subjects of European descent (GA vs GG odds ratio (OR) (95% confidence interval (CI)): 0.89(0.826-0.968), \( P = 0.00562 \), and AA vs GG OR(95% CI): 0.892(0.800-0.996), \( P = 0.0415 \)). The population attributable risk for obesity related to these odds ratios was 0.8% for the GG genotype in the combined meta-analysis and 1.8% in the Steno/Inter99 study group. Thus, in line with our data from the Steno/Inter99 study group this meta-analysis confirms that the common G-allele is associated with obesity.

Impact of –866G>A on quantitative traits

We analysed a range of quantitative metabolic traits in relation to –866G>A in the Inter99 study population (Table 2). Fasting plasma glucose and serum insulin were significantly higher among the GG genotype (\( P = 0.02 \) and \( P = 0.002 \)). G-allele carriers were more insulin resistant as estimated by the homoeostasis model assessment (HOMA-IR) (\( P = 0.0007 \)), which was confirmed by a decreased insulin sensitivity index estimate (BIGTT-S, \( P = 0.03 \)). In the sample of 377 young, healthy Caucasians who underwent a tolbutamide-modified IVGTT carriers of the G-allele had decreased insulin sensitivity (\( P = 0.05 \)), although most prominently when using a recessive model (Table 3).

Although the GG genotype was significantly associated with obesity in the Inter99/Steno study group and in the meta-analysis, BMI according to genotype was not affected in the Inter99 or ADDITION study groups (Table 2 and Supplementary Table B). In the sample of 377 young, healthy Caucasians, fat percentage was lower in GG-carriers (mean ± s.d.: GG 22 ± 8%, GA 24 ± 7%, AA 23 ± 9%, \( P = 0.02 \)), but BMI was unchanged (Table 3). For waist-to-hip ratio, waist circumference, fasting serum lipids and blood pressure we found no relationship with the –866G>A polymorphism (Tables 2 and 3 and Supplementary Table B). Analyses were made with adjustment for age and sex and both with and without adjustment for BMI, but this did not essentially change the results.

DISCUSSION

Our main positive finding was the association of the UCP2 –866G>A polymorphism with insulin resistance among 5781 middle-aged Danes and in 377 young, healthy Danes, where subjects with the G-allele consistently had lower insulin sensitivity. The second positive finding was a decreased OR for obesity.
of the UCP2 –866G-A allele in a meta-analysis comprising 12,984 subjects. The population attributable risk for obesity for the combined meta-analysis was 0.8%, which is low but in the range previously found for obesity- or diabetes-associated gene variants.52 However, when examining quantitative traits, BMI was not increased by this variant. Thus, although the variant was associated with obesity, its action may primarily be due to lower peripheral insulin sensitivity as this quantitative trait was consistently lower in GG genotype carriers.

Insulin resistance has been reported to be causally linked with oxidative stress,53 and absence of UCP2 increases superoxide production6 and causes oxidative stress.9 Overexpression of UCP2 in cells decreases their nutrient-induced generation of reactive oxygen species.54 The widespread expression pattern of UCP2 makes possible a dual function in obesity (energy metabolism) and type 2 diabetes (glucose metabolism),55 which is consistent with our findings that this variant is associated with decreased insulin sensitivity and obesity among G-allele carriers. The G-allele of the –866G-A polymorphism, based on its lower cis-acting capability, is predicted to be associated with increased reactive oxygen species levels and insulin resistance. Obesity increases UCP2 expression in various tissues,1 and a possible mechanism for the observed association between the –866G-A allele and both insulin resistance and obesity is that the obesity-induced increase of UCP2 mRNA could be lower for the –866G-allele compared with the A-allele, resulting in increased reactive

---

**Table 1.** Meta-analysis of obesity (a) and type 2 diabetes (b). The meta-analysis of obesity uses data from references14,15,18,29,31 in addition to data obtained in the present study. The meta-analysis of type 2 diabetes uses data from references17,20,21,23,35,38,50,58,59 in addition to data from the present study.

```
<table>
<thead>
<tr>
<th>Study</th>
<th>Odds-ratio vs. GG</th>
<th>% weight (reference)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esterbauer et al 2001a</td>
<td>AA GA</td>
<td>4 (14)</td>
</tr>
<tr>
<td>Esterbauer et al 2001b</td>
<td>AA GA</td>
<td>5 (14)</td>
</tr>
<tr>
<td>Dalgaard et al 2003</td>
<td>AA GA</td>
<td>12 (15)</td>
</tr>
<tr>
<td>Schäuble et al 2003</td>
<td>AA GA</td>
<td>3 (31)</td>
</tr>
<tr>
<td>Mancini et al 2003</td>
<td>AA GA</td>
<td>4 (18)</td>
</tr>
<tr>
<td>Ochoa et al 2007</td>
<td>AA GA</td>
<td>3 (29)</td>
</tr>
<tr>
<td>Present (Steno/Inter99)</td>
<td>AA GA</td>
<td>35</td>
</tr>
<tr>
<td>Present (ADDITION)</td>
<td>AA GA</td>
<td>30</td>
</tr>
<tr>
<td>All studies (n=12984)</td>
<td>AA GA</td>
<td></td>
</tr>
</tbody>
</table>

OR (95% CI):
0.892 (0.800-0.996)
0.894 (0.826-0.968)
```

```
<table>
<thead>
<tr>
<th>Study</th>
<th>Odds-ratio vs. GG</th>
<th>% weight (reference)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Krempler et al 2004</td>
<td>AA GA</td>
<td>4 (35)</td>
</tr>
<tr>
<td>D’Adamo et al 2004</td>
<td>AA GA</td>
<td>7 (20)</td>
</tr>
<tr>
<td>Ji et al 2004</td>
<td>AA GA</td>
<td>2 (21)</td>
</tr>
<tr>
<td>Bulotta et al 2005</td>
<td>AA GA</td>
<td>7 (23)</td>
</tr>
<tr>
<td>Rai et al 2007</td>
<td>AA GA</td>
<td>11 (38)</td>
</tr>
<tr>
<td>Heidari et al 2010</td>
<td>AA GA</td>
<td>1 (50)</td>
</tr>
<tr>
<td>Sasahara et al 2004</td>
<td>AA GA</td>
<td>4 (17)</td>
</tr>
<tr>
<td>Pinelli et al 2006</td>
<td>AA GA</td>
<td>4 (58)</td>
</tr>
<tr>
<td>Beitelsees et al 2010</td>
<td>AA GA</td>
<td>3 (59)</td>
</tr>
<tr>
<td>Present</td>
<td>AA GA</td>
<td>57</td>
</tr>
<tr>
<td>All studies (n=15107)</td>
<td>AA GA</td>
<td></td>
</tr>
</tbody>
</table>

OR (95% CI):
0.963 (0.870-1.06)
0.967 (0.901-1.04)
```
Table 2. Anthropometric and metabolic characteristics of 5781 middle-aged untreated Danes (Inter99) stratified according to UCP2 – 866G>A genotypes

<table>
<thead>
<tr>
<th></th>
<th>GG</th>
<th>GA</th>
<th>AA</th>
<th>β (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (men/women)</td>
<td>2164 (1087/1077)</td>
<td>2694 (1331/1363)</td>
<td>923 (451/472)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>46 ± 8</td>
<td>46 ± 8</td>
<td>46 ± 8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.2 ± 4.4</td>
<td>26.2 ± 4.6</td>
<td>26.1 ± 4.6</td>
<td>−0.02 (−0.18; 0.15)</td>
<td>0.9</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>86 ± 13</td>
<td>87 ± 13</td>
<td>86 ± 14</td>
<td>0.17 (−0.03; 0.36)</td>
<td>0.09</td>
</tr>
<tr>
<td>Waist-to-hip ratio</td>
<td>0.86 ± 0.08</td>
<td>0.86 ± 0.09</td>
<td>0.86 ± 0.09</td>
<td>0.001 (−0.001; 0.003)</td>
<td>0.2</td>
</tr>
</tbody>
</table>

Plasma glucose (mmol l⁻¹)

- **Fasting**: 5.6 ± 0.9, 5.5 ± 0.8, 5.5 ± 0.7, −0.03 (−0.06; −0.01), 0.02
- **30-min**: 8.8 ± 2.0, 8.6 ± 1.8, 8.7 ± 1.8, −0.05 (−0.11; 0.02), 0.2
- **120-min**: 6.3 ± 2.2, 6.2 ± 2.1, 6.2 ± 2.1, −0.04 (−0.11; 0.04), 0.3
- **AUC**: 223 ± 136, 218 ± 135, 220 ± 132, −1.67 (−6.46; 3.11), 0.5

Serum insulin (pmol l⁻¹)

- **Fasting**: 35 (25–53), 34 (23–50), 32 (23–49), −3.0% (−4.9; −1.1), 0.002
- **30-min**: 247 (176–355), 246 (176–351), 236 (170–348), −1.1% (−3.1; 0.8), 0.3
- **120-min**: 158 (101–259), 156 (95–254), 152 (90–251), −4.0% (−6.7; −1.2), 0.005
- **AUC**: 18 870 (13 120–27 740), 18 680 (13 100–27 100), 18 270 (12 740–26 670), −1.8% (−3.9; 0.4), 0.1

Insulin resistance (mmol l⁻¹ × pmol l⁻¹)

- **HOMA-IR**: 8.7 (5.8–13.4), 8.1 (5.5–12.7), 7.9 (5.4–12.2), −3.5% (−5.5; −1.5), 0.0007
- **BIGTT-S₁**: 9.1 ± 4.1, 9.3 ± 4.1, 9.5 ± 4.1, 0.17 (0.02; 0.33), 0.03

Fasting serum lipids (mmol l⁻¹)

- **Triglyceride**: 1.1 (0.8–1.6), 1.1 (0.8–1.5), 1.0 (0.8–1.5), −1.4% (−3.2; 0.4), 0.1
- **Total cholesterol**: 5.5 ± 1.1, 5.5 ± 1.1, 5.5 ± 1.1, −0.002 (−0.040; 0.035), 0.9
- **HDL-cholesterol**: 1.4 ± 0.4, 1.4 ± 0.4, 1.4 ± 0.4, −0.003 (−0.016; 0.010), 0.7

Abbreviations: AUC, area under the curve; BIGTT-S₁, BIGTT-insulin sensitivity index; BMI, body mass index; CI, confidence interval; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance. Data are unadjusted mean ± s.d. or medians (interquartile range). Values of serum insulin, values derived from insulin variables and values of serum triglyceride were logarithmically transformed before statistical analysis and their effect sizes (β) are presented as the increase/decrease in percent. All analyses were made using an additive genetic model, adjusted for age, sex and BMI (BMI was adjusted for age and sex). HOMA-IR was calculated as fasting plasma glucose (mmol l⁻¹) multiplied by fasting serum insulin (pmol l⁻¹) and divided by 22.5. BIGTT-S₁ was calculated as described.47

Table 3. Anthropometric and metabolic characteristics of 317 young, healthy Danes stratified according to UCP2 – 866G>A genotypes

<table>
<thead>
<tr>
<th></th>
<th>GG</th>
<th>GA</th>
<th>AA</th>
<th>β (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (men/women)</td>
<td>129 (72/57)</td>
<td>146 (71/75)</td>
<td>42 (23/19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>25 ± 3</td>
<td>26 ± 3</td>
<td>25 ± 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.4 ± 3.6</td>
<td>23.7 ± 3.4</td>
<td>24.3 ± 5.2</td>
<td>0.49 (−0.10; 1.09), 0.08</td>
<td></td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>78 ± 10</td>
<td>78 ± 10</td>
<td>80 ± 14</td>
<td>−0.10 (−0.86; 0.65), 0.56</td>
<td></td>
</tr>
<tr>
<td>Waist-to-hip ratio</td>
<td>0.82 ± 0.07</td>
<td>0.82 ± 0.06</td>
<td>0.82 ± 0.08</td>
<td>0.001 (−0.006; 0.009), 0.5</td>
<td></td>
</tr>
<tr>
<td>Fat mass (kg)</td>
<td>17 ± 8</td>
<td>17 ± 7</td>
<td>18 ± 11</td>
<td>−0.23 (−0.59; 0.13), 0.2</td>
<td></td>
</tr>
<tr>
<td>Fat percentage (%)</td>
<td>22 ± 8</td>
<td>24 ± 7</td>
<td>23 ± 9</td>
<td>−0.40 (−0.85; 0.04), 0.02</td>
<td></td>
</tr>
</tbody>
</table>

Plasma glucose (mmol l⁻¹)

- **Fasting**: 5.0 ± 0.4, 5.0 ± 0.5, 5.0 ± 0.6, 0.01 (−0.06; 0.08), 0.8

Serum insulin (pmol l⁻¹)

- **Fasting**: 29 (23–41), 31 (24–48), 32 (25–52), 1.5% (−5.5; 8.5), 0.9

Insulin action

- **Acute insulin response (min pmol l⁻¹)**: 1929 (1147–2601), 1959 (1278–2858), 1760 (1006–2630), −5.5% (−16.7; 5.7), 0.1
- **Insulin sensitivity (10⁻⁶ × (min pmol l⁻¹)⁻¹)**: 13 (9–20), 13 (8–18), 14 (11–23), 2.4% (−6.6; 11.4), 0.05

Disposition index

- **Prec**: 28 040 (16 750–37 090), 24 540 (13 930–38 500), 29 400 (17 890–43 110), −3.1% (−16.1; 10.0), 0.5

Fasting serum lipids (mmol l⁻¹)

- **Triglyceride**: 0.9 (0.7–1.2), 0.9 (0.7–1.2), 0.9 (0.7–1.3), 5.4% (−1.4; 12.2), 0.2
- **Total cholesterol**: 4.5 ± 0.9, 4.5 ± 0.8, 4.6 ± 1.1, 0.01 (−0.13; 0.14), 0.7
- **HDL-cholesterol**: 1.2 ± 0.3, 1.2 ± 0.3, 1.1 ± 0.3, −0.01 (−0.05; 0.03), 0.03

Abbreviations: BMI, body mass index; CI, confidence interval; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance. Data are unadjusted mean ± s.d. or medians (interquartile range). Values of serum insulin, values derived from insulin variables and values of serum triglyceride were logarithmically transformed before statistical analysis and their effect sizes (β) are presented as the increase/decrease in percent. All analyses were made using a recessive genetic model, adjusted for age, sex and BMI (BMI was adjusted for age and sex). HOMA-IR was calculated as fasting plasma glucose (mmol l⁻¹) multiplied by fasting serum insulin (pmol l⁻¹) and divided by 22.5. BIGTT-S₁ was calculated as described.47 Acute insulin response was calculated as the area under the insulin curve from 0 to 8 min.
oxygen species generation and insulin resistance in G-allele carriers.

This promoter variant of UCP2 has been extensively studied with respect to many different traits associated with obesity or type 2 diabetes; however, the current study is by far the largest performed to date. Although several studies have shown that this promoter variant changes reporter gene activity, it may not be the (only) functional variant: The UCP3-UCP2 genomic region was investigated for 14 SNPs (single-nucleotide polymorphisms) (including −866G/A) spanning the UCP2 and UCP3 loci among 3782 women of different ethnicities. Although no single SNP was associated with type 2 diabetes after correction for multiple testing, haplotype analysis indicated an increased type 2 diabetes risk among Greek women, and this effect was further accentuated by overweight although no association with BMI was observed. The four-SNP haplotype in question was in high linkage disequilibrium with the −866A-allele, suggesting that yet unidentified variation covered by the haplotype-spanned area may be responsible for the observed relationships of −866G/A with metabolic variables. The UCP2 –866G/A polymorphism was also genotyped in the genome-wide association study performed by the Welcome Trust Case Control Consortium, but was not associated with type 2 diabetes. In the Diabetes Genetics Initiative study, the polymorphism was not genotyped. In a recent meta-analysis of both and other variants of the UCP3-UCP2 gene locus, the −866G/A polymorphism was not associated with increased risk of type 2 diabetes. The present study confirms and extends these conclusions.

In Austrian subjects, the G-allele of the −866G/A polymorphism was also found to associate with obesity, whereas fasting insulin was lower in Austrians carrying the GG genotype. In these subjects, UCP2 mRNA levels in visceral fat were decreased in subjects of the GG genotype. Decreased insulin sensitivity has been detected in Italians carrying the AA genotype, whereas we observed the opposite. Although the current SNP has different cis-acting capability of its alleles (the A-allele giving higher promoter activity), these observations in line with Hsu et al. point to the possibility that yet unidentified variants may account for the effect on insulin resistance.

Insulin resistance (HOMA-IR) has been reported to be positively correlated with visceral adipose tissue UCP2 mRNA expression in 100 obese Italians undergoing laparoscopic gastric banding, whereas fasting plasma insulin levels alone are negatively correlated with UCP2 mRNA expression in subcutaneous abdominal fat. However, a difference between expression levels and regulation of expression between different fat depots cannot be excluded. In conclusion, using a study of a total of 17 636 Danes we show that the UCP2 –866G–A polymorphism is associated with decreased insulin sensitivity and obesity. In addition, we confirmed the association with obesity by carrying out meta-analyses with obesity and type 2 diabetes of our data combined with publicly available data.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This study was supported by the Danish Medical Research Council, the Danish Diabetes Association, the Gerda and Aage Haensch Foundation, the AP Møller Foundation for the Advancement of Medical Science, Novo Nordisk A/S and University of Copenhagen. Further, this work is supported by the European Commission as an integrated project under the 6th Framework Programme (LSHM-CT-2005-018734, HepAdip). The Danish Obesity Research Centre (DanORC; www. danorc.dk) is supported by the Danish Council for Strategic Research (grant 2101-06-0005). We wish to thank Annette Forman, Tina Lorenzen and Marianne Stendal for technical assistance, AL Nielsen for data management, and Grete Lademann for secretarial support.

REFERENCES


Supplementary Information accompanies the paper on International Journal of Obesity website (http://www.nature.com/ijo)